DTDaria V. Turchak

Daria V. Turchak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daria V. Turchak has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Change in the susceptibility of multidrug-resistant Gram-negative pathogens to third-generation cephalosporins and fluoroquinolones after the introduction of preauthorization

    by M.V. Khaitovych, O.O. Vitіuk, S.P. Krasyuk, D.V. Turchak, I. Niecwietajewa

    Background. Antimicrobial resistance among Gram-negative bacteria is one of the most important challenges in modern surgery, as it significantly complicates the treatment of infections, increases mortality, length of stay, and healthcare costs. Objective: to assess changes in the antimicrobial susceptibility of multidrug-resistant Gram-negative pathogens following the introduction of preauthorization system for antibacterial therapy. Materials and methods. A retrospective analysis of local microbiological surveillance data was performed. Particular attention was paid to changes in the susceptibility of Klebsiella pneumoniae and Acinetobacter baumannii to third-generation cephalosporins and fluoroquinolones. Results. Following the introduction of preauthorization, a positive trend was observed in the antimicrobial susceptibility of the major Gram-negative bacteria. The susceptibility of Klebsiella pneumoniae to third-generation cephalosporins increased from 28.6 % in 2023 to 50.0 % in 2025, to ciprofloxacin from 42.9 to 64.0 %, to amikacin from 42.9 to 64.0 %, and to meropenem from 42.9 to 50.0 %. After a temporary decrease in susceptibility to cephalosporins and fluoroquinolones in 2024, a substantial recovery was observed in 2025. Regarding Acinetobacter baumannii, the most pronounced changes were observed for third-generation cephalosporins and fluoroquinolones: whereas virtually no susceptible isolates were identified in 2023–2024, approximately 42 % of strains were susceptible to these agents in 2025. An increase in susceptibility to amikacin and carbapenems was also observed. These findings indicate a gradual reduction in selective pressure following restrictions on the use of ceftriaxone and levofloxacin and support the feasibility of preauthorization introduction into comprehensive antimicrobial stewardship programs. Conclusions. Preauthorization of broad-spectrum antibiotics is associated with improved local susceptibility of multidrug-resistant Gram-negative pathogens, primarily Klebsiella pneumoniae and Acinetobacter baumannii, to third-generation cephalosporins and fluoroquinolones.

  • Open Access

    The Analysis of Changing in Oseltamivir Use and Influenza Vaccination in Ukraine (2019—2025)

    by M.V. Khaitovych, O.A. Golubovska, D.V. Turchak, D.S. Poliakova, O.V. Bezrodna

    Objective — to assess trends in oseltamivir use in Ukraine from 2019 to 2025 and to analyse its associa­tion with influenza vaccination, as well as morbidity and hospitalisation rates. Materials and methods. The study used data from the PharmXplorer analytical system (Proxima Research) on quarterly retail dispensing of oseltamivir (expressed in defined daily doses, DDDs) and influenza vaccines in the Ukrainian pharmacy segment. Official data from the Public Health Center of the Ministry of Health of Ukraine on influenza incidence and vaccination rates were analysed, along with hospitalisation statistics of patients with influenza admitted to the infectious disease department of a clinical hospital in Kyiv during 2023—2025. Trend analysis and correlation analysis were applied. Results and discussion. The results demonstrated an exponential increase in oseltamivir consumption after 2023, with peak values observed in the first quarter of 2025 (3,170.48 thousand DDDs), which was 6.5-fold higher than in 2020. In contrast, the volume of influenza vaccine dispensing in the fourth quarter of 2024 decreased by 3.5-fold compared to 2019. A seasonal correlation was identified between peaks in vaccine procurement in the fourth quarter and increased oseltamivir consumption in the first quarter of the subsequent year (r = 0.3; p < 0.05). Concurrently, an upward trend in influenza-related hospitalisation was observed in 2024—2025. The study discusses the clinical efficacy, pharmacokinetic and potential risks associated with excessive oseltamivir use, including adverse reactions and the development of antiviral resistance. Conclusions. The sharp increase in oseltamivir use against the background of declining influenza vaccination rates may indicate insufficient preventive immunisation and a reactive approach to aetiotropic therapy. The findings substantiate the need to strengthen influenza vaccination programmes, particularly among high-risk groups, and to optimise antiviral prescribing practices in accordance with national clinical guidelines.


  • Open Access

    Directions of Optimizing Antibiotic Therapy of Elderly Patients with Coronavirus Disease

    by О.а. Голубовська, O.V. Bezrodna, D.V. Turchak

    The course of coronavirus disease 2019 (COVID-19) in elderly patients is often accompanied by the development of pneumonia with the addition of a secondary bacterial infection, which requires the additional use of antibacterial agents. Objective — to evaluate risks and define approaches for optimising antibacterial therapy in elderly patients with COVID-19 who required hospitalization due to pneumonia and existing respiratory failure. Materials and methods. A retrospective analysis of the medical records of 29 patients aged 70 to 94 years (mean age (79.7 ± 7.5) years) who were hospitalised in the department of infectious diseases with a confirmed diagnosis of COVID-19 and community-acquired viral-bacterial pneumonia was conducted. All patients had comorbid cardiovascular pathology, and 8 patients had type 2 diabetes mellitus. The risks of antibacterial use were assessed using the FORTA (Fit for The Aged) classification, as well as the AWaRe classification adapted by the Ministry of Health of Ukraine. Results and discussion. A high frequency (41.4 %) of fluoroquinolone antibiotic use was revealed among elderly patients. According to the FORTA classification, these include drugs from group C (moxifloxacin) or D (ciprofloxacin), which is associated with reduced safety of pharmacotherapy, especially in the context of polypharmacy. At the same time, none of the patients received safer antibacterial agents from group A. Only one Access group drug was prescribed according to the AWaRe classification — clindamycin; 28 prescriptions involved Watch group antibacterial agents; 12 prescriptions — Reserve group agents (ceftriaxone). Conclusions. Half of the elderly patients with COVID-19 and community-acquired viral-bacterial pneumonia received antibacterial drugs with a high risk of adverse reactions. Among the directions for therapy optimisation are the minimisation of fluoroquinolone use and replacement of ceftriaxone with cefotaxime.

  • Open Access

    APPLICATION OF ARTIFICIAL INTELLIGENCE IN CLINICAL PHARMACOLOGY (LITERATURE REVEW)

    by Mykola V. Khaitovych, Daria V. Turchak

    Background. Clinical pharmacology is a scientific discipline that covers all aspects of the interaction between drugs and humans. Aim: to review current data on the possibility of using artificial intelligence (AI) to optimize scientific research, practical application and education in clinical pharmacology. Materials and methods. Analysis of data presented in PubMed, using the keywords "clinical pharmacology", "artificial intelligence". Results. It was found that AI is used at all stages of drug development from molecule discovery to real clinical practice. In particular, AI provides prediction of the pharmacokinetics and pharmacodynamics of drugs, the need for monitoring therapy, and the risk of drug interactions. The introduction of AI-based programs (for example, ChatGPT) into the activities of modern clinics allows to increase the accuracy of prescriptions (up to 50%), reduce repeat hospitalizations (up to 58%) and reduce administrative costs. AI models allow to individualize the dose, in particular for drugs with a narrow therapeutic index (for example, vancomycin); determine the dose taking into account pharmacogenetic reactions; accurately identify the risk of drug interactions and offer clinical solutions. In the educational sphere, the use of ChatGPT allows to simulate clinical situations, accelerating the creation of cases and test tasks (although almost 30% of the generated tasks were unsuitable without expert revision); promotes the development of clinical thinking in students; forms decision-making skills. Among the problems of using AI in clinical pharmacology, in addition to the need for expert assessment of data quality, issues of ethics, confidentiality and dual use of technologies (for example, the risks of developing bioweapons) are of great importance, therefore it is important to combine the capabilities of AI with the experience of specialists. Conclusion. Artificial intelligence has great potential for organizing clinical trials; optimizing the therapeutic effects of drugs, taking into account the risk of pharmacogenetic reactions and drug interactions, improving clinical decision-making and patient safety; and learning personalized drug use. It is important to use AI tools in conjunction with expert judgment from healthcare professionals, and to properly consider regulatory considerations, data privacy, and ethical implications.


  • Open Access

    CHALLENGES IN IMPLEMENTING ANTIMICROBIAL STEWARDSHIP IN HEALTHCARE INSTITUTIONS: SURVEY RESULTS OF PHYSICIANS AND PHARMACISTS

    by Mykola V. Khaitovych, Ольга А. Голубовська, Leonid L. Pinskyi, Vladyslav Yu. Rafalskyi, Daria V. Turchak, Olena A. Temirova, Микола В. Хайтович, Владислав Ю. Рафальський

    Introduction. Antimicrobial stewardship (AMS) is considered a key strategy for preventing and addressing the problem of antimicrobial resistance. Most recent data on challenges in AMS implementation come from well-resourced hospitals and high-income countries. It remains unclear whether the findings of these studies can be applied to resource-limited hospitals [3]. Aim. To examine the challenges identified by healthcare professionals in implementing AMS in healthcare institutions in Ukraine. Materials and methods. An anonymous online survey was conducted between November 11 and December 20, 2024, involving 146 specialists (50 pharmacists and 96 physicians) responsible for AMS implementation in various healthcare institutions across Ukraine. The reliability of differences in the frequency of certain features was analyzed using the chi-square test. Results. The study noted a decrease in overall antimicrobial consumption, adherence to documenting antimicrobial prescriptions in medical records, a reduction in the duration of antimicrobial therapy, and shorter durations of intravenous antibiotic administration. Pharmacists were significantly more likely than physicians to report a reduction in the use of reserve group drugs (85.7% vs. 55.2%, p=0.0035). Insufficient microbiological diagnostic support was reported by 61% of respondents, communication challenges in coordinating antimicrobial therapy by 44.5%, difficulties in teamwork development by 35.6%, antibiotic shortages by 28.8%, lack of time by 23.3%, inadequate administrative support by 20.5%, insufficient regulatory support by 19.9%, and challenges in creating standard operating procedures (SOPs) by 19.2%. Training prescribers of antimicrobial agents was considered the most significant intervention by 45.9% of respondents; 13% cited preauthorization; 8.9% mentioned prospective audit with feedback; 8.2% each mentioned optimizing the duration of antimicrobial therapy and developing SOPs; and 2.7% identified stepwise therapy. Conclusions. Three main groups of challenges in AMS implementation were identified: insufficient material resources, lack of prioritization of AMS measures by hospital administration, and socio-psychological barriers that hinder communication. The reduction in the use of reserve group antibiotics was predominantly achieved through passive AMS interventions.


  • Open Access

    Modern Directions of Optimization of Empirical Antimicrobial Therapy of Community-Acquired Pneumonia (Review)

    by M.V. Khaitovych, D.V. Turchak, V.V. Ulishchenko, V.YU. Rafalskyi

    Severe community-acquired pneumonia (CAP) remains a life-threatening disease, causing 78 % of infection-related deaths and is the most common cause of sepsis. Empirical antibiotic therapy is started before the results of bacteriological diagnosis are available. The diversity of pathogens often makes it difficult to choose a drug for etiotropic empirical therapy. Isolates of bacteria responsible for CAP sometimes show high resistance to several antibiotics, including cephalosporins and carbapenems. We analyzed scientific publications from the PubMed database for the last 5 years on the problem of empirical antimicrobial therapy of CAP. Currently, empirical therapy for pneumonia is determined by the site of infection (hospital or other settings), but may be conditioned by the presence of risk factors for multidrug-resistant pathogens, regardless of the site of infection. A rational approach to making decisions about prescribing broad-spectrum antibiotics is to use risk prediction models at the patient level. Recommendations for empirical therapy of CAP have been developed, taking into account individual risk factors for multidrug-resistant infection, and their use, according to the results of 30-day mortality, has proven to be more effective than the use of classification by site of pneumonia.Among the current directions of empirical antimicrobial therapy of CAP are use of drugs with a narrow spectrum of action based on the use of an algorithm for determining the risk of multidrug-resistant infection, as well as a procalcitonin test; use of an algorithm for choosing an alternative antimicrobial agent in case of a history of penicillin allergy; reduction of the total duration of antimicrobial therapy; widespread introduction of antimicrobial stewardship programs in the activities of not only hospitals but also primary care facilities.

  • Open Access

    PRE-AUTHORIZATION OF ANTIBACTERIAL DRUGS IN THE TREATMENT OF CHILDREN WITH ACUTE PERIANAL ABSCESS

    by M.V. Khaitovych, N.P. Kysil, О.а. Temirova, O.M. Holovnia, D.V. Turchak, V.O. Polovynka

    Relevance. Acute perianal abscess mainly occurs in boys in the first year of life, but can occur in girls and in older age, often progressing to anal fistula. After surgery and drainage, it is advisable to administer antibiotics because antibiotic therapy reduces the risk of fistula. Objective is to evaluate the possibility of using antibacterial drugs, mainly Access and Watch groups with a narrow spectrum of action, in the treatment of children with perianal abscess. Materials and methods. A retrospective analysis of the results of treatment of 26 boys and 4 girls aged 3 months to 17 years. The study of biological material was performed by the culture method. Species identification of microorganisms was performed on automatic microbiological analyzers Vitek2Compact (bioMerieux) and VitekMS (bioMerieux). All children underwent surgical removal of the crypt and drainage of the abscess. Antibacterial therapy was prescribed for a period of 3 to 12 days, depending on the course of the disease and the results of microbiological monitoring. Results. A total of 48 prescriptions of antibacterial agents were made, of which 33 (68.7%) were antibacterial agents from the Access group. 16 children were treated only with Access group antibacterial drugs. Of these, 14 children, mostly in the first year of life, received only narrow-spectrum antibacterial agents (amikacin in monotherapy or in combination with metronidazole, clindamycin). In the scheme of treatment of children 14 children, mostly older people included a drug from the group of cephalosporins of the third generation. Half of these patients also received amikacin and 3 received metronidazole. Conclusions. Children with acute perianal abscess in the first year of life should be treated as mono- or combination therapy with narrow-spectrum drugs from the Access group, while older children - with the inclusion of a combination of antimicrobial drugs broad-spectrum drugs Watch group.

  • Open Access

    PROBLEMATIC POLYPHARMACY IN OUTPATIENT THERAPY OF CHILDREN: POTENTIAL RISKS OF DRUG INTERACTIONS

    by M.V. Khaitovych, V. A. Sova, K. Yu. Kyrylchuk, І.м. Sytnyk, V.O. Polovynka, О.а. Теmіrоvа, D.V. Turchak

    Relevance. The development of medical and pharmaceutical technologies has allowed ensuring the quality of life of children even with severe chronic diseases, but often the treatment of such children is associated with polypharmacy. Objective is to assess the risks of drug interactions in children with polypharmacy. Materials and methods. The course of pharmacotherapy of 54 children with atopic diseases, diseases of the gastrointestinal tract, parasitic infestation, inflammatory diseases of the genital organs, etc. aged from birth to 17 years, who received simultaneously from 5 to 11 drugs (average 6.4 ± 1.5 drugs) Results. Problematic polypharmacy was founded in 31 children (75.0% of schoolchildren and 38.5% of preschool children) with polypharmacy. Among them, 22 patients (71.0%) had pharmacokinetic risks, and 17 children (54.8%) had pharmacodynamic interactions. Among the causes of pharmacokinetic interaction – the use of inhibitors (omeprazole, etc.) and inducers (phenobarbital, St. John's wort, etc.) metabolism, pharmacodynamic interaction – the simultaneous use of several glucocorticoids, drugs with similar organ toxicity, and more. Conclusions. Outpatient use of 5 or more drugs is combined in more than half of children at risk of their interaction, development of side effects or reduced effectiveness of treatment.


  • Open Access

    CLINICO-PHARMACOLOGICAL ASPECTS OF OVARIAN-MENSTRUAL CYCLE SUPPORT. Review

    by D.V. Turchak, M.V. Khaitovych

    Relevance. It is known that 12.5% of women suffer from infertility. Correction of menstrual disorders is an important way to maintain a woman's reproductive health. Objective is to consider current data on the physiology, etiopathogenesis and pharmacotherapy of women with ovarian-menstrual disorders. Methods. Analysis of the data presented in PubMed, by keywords "ovarian-menstrual cycle", "pharmacological support". Results. Modern data on physiology, humoral regulation of the ovarian-menstrual cycle are presented. The role of positive and negative feedback between estradiol and progesterone levels and the activity of anterior pituitary gonadotropic hormones and insulin regulatory pathways is emphasized. The main changes of the central nervous system and behavioral features depending on the phase of the menstrual cycle are described. The directions of pharmacological support and stimulation of ovulation are described. The mechanisms of action and indications for the use of oral hypoglycemic and gonadotropic drugs, the benefits and place of each in the maintenance and stimulation of the ovarian-menstrual cycle are presented. Metformin is effective in clomiphene-resistant women and may be combined with clomiphene, particularly in the treatment of polycystic ovary syndrome (PCOS). Sitagliptin improves ovulation in PCOS, is more effective in combination with metformin. Gonadotropins stimulate the ovaries, promoting the production and maturation of eggs, progesterone prepares the inner layer of the uterus to fix the embryo and helps to bear fruit. They are mainly used in women with PCOS in whom other drugs are ineffective.Some results of pharmacogenetic researches, efficiency, in particular, use of follicle-stimulating hormone depending on genetic polymorphisms of its receptor are noted. Conclusions. In modern conditions, the use of pharmacological agents is an important area of support and stimulation of the ovarian-menstrual cycle to improve female reproductive function.

  • Open Access

    JILBER’S SYNDROME: CLINICAL AND PHARMACOLOGICAL ASPECTS. Review

    by M.V. Khaitovych, D.V. Turchak

    Relevance. At present, the metabolism of drugs in patients with Gilbert's syndrome will be actively studied, as it may be associated with both the risk of dose-dependent adverse reactions and treatment ineffectiveness. Objective: to summarize the information of various authors on the peculiarities of the use of drugs in patients with Gilbert's syndrome. Methods. Analysis of scientific publications in the international electronic scientometric database PubMed by keywords. Search depth - 10 years (2010-2019). Results. Gilbert’s syndrome is observed in 3-10% of the population and is characterized by an isolated increase of bilirubin in the blood to moderate values without changes in other biochemical parameters of liver function and without damage to its structure. Gilbert's syndrome is inherited autosomal recessively and is mainly due to the presence of an additional dinucleotide thymine-adenine (TA) in the promoter region A(TA)6TAA gene encoding the enzyme UGT1A1. Elongation of the promoter sequence reduces the formation of UGT1A1. Invariant A(TA)7TAA, the level of enzyme production can be reduced to 80% of the norm in hetero- and up to 20% in homozygotes, respectively. Gilbert’s syndrome is manifested by increased levels of indirect bilirubin in the blood, jaundice of the skin and mucous, abdominal pain, as well as dyspepsia, and asthenovegetative syndrome. Intermittent icteric sclera and skin occur against the background of exogenous and endogenous factors such as starvation, dehydration, infectious diseases, emotional and physical stress, hemolysis, menstruation, alcohol consumption, hormonal contraception, etc., usually at a bilirubin concentration exceeding 40-45 μmol/l. Complications of hyperbilirubinemia with Gilbert’s syndrome include the development of gallstone disease, including in children and adolescents. Gilbert’s syndrome is associated with impaired metabolism of some drugs – aglucones. These include anabolic steroids, glucocorticoids, androgens, rifampicin, cimetidine, chloramphenicol, streptomycin, sodium salicylate, ampicillin, caffeine, Ethinyl estradiol, paracetamol, ibuprofen, The clinical feature of Gilbert’s syndrome is the appearance or aggravation of jaundice associated with the use of such drugs. In conditions of UGT1 deficiency, drugs compete with bilirubin for the enzyme, which leads to an increase of indirect bilirubin in the serum. Therefore, to prevent liver damage, it is necessary to assess the risk and benefit of drug treatment of patients with Gilbert’s syndrome in each case. Conclusions. Gilbert’s syndrome is a common pathological condition and therefore it is important to diagnose it as early as possible. Given that the use of aglucones in patients with Gilbert's syndrome may cause the development of drug-induced liver damage, it is necessary to assess the risk and benefit of drug treatment of patients with Gilbert’s syndrome in each case.